ExploreWatchlistsPricing
  1. JP-listed companies
  2. CHUGAI PHARMACEUTICAL CO., LTD.
  3. Financials
  4. Income before tax

CHUGAI PHARMACEUTICAL CO., LTD. (4519)

Market cap
¥14.02T
P/E ratio
34.2x
Chugai Pharmaceutical develops and sells prescription medicines in Japan and internationally, with research operations spanning the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Dec 31, 2025597,807+10.09%
Dec 31, 2024543,034+22.35%
Dec 31, 2023443,821-16.44%
Dec 31, 2022531,166+26.65%
Dec 31, 2021419,385+40.64%
Dec 31, 2020298,188+43.43%
Dec 31, 2019207,893+71.18%
Dec 31, 2018121,449+25.17%
Dec 31, 201797,031+30.33%
Dec 31, 201674,448-14.70%
Dec 31, 201587,276+14.59%
Dec 31, 201476,164-2.06%
Dec 31, 201377,764+3.13%
Dec 31, 201275,406+18.59%
Dec 31, 201163,585

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat